---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117735"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:48:21.261143+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NRx Pharma Q3 net loss narrows to $6.1M; advances NRX-101 and ketamine plans

## Summary
- Q3 net loss $6.1M vs $9.1M YoY; R&D expense $3.3M, G&A $2.5M; cash $8.9M.
- Near completion of Phase 2b/3 NRX-101 trial for treatment-resistant bipolar depression; top-line data expected shortly after last patient visit.
- Plan to submit NDA for IV ketamine (NRX-100) in Q1 2024; manufacturing partnership with Nephron signed.
- Received term sheet for up to $30M anchor financing for a ketamine-focused spinoff entity.
- Identified naked shorting disparities of ~1-1.5M shares; counsel instructed to demand closure of uncovered positions.

## SEC filing metadata
- accession: 0001104659-23-117735
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465923117735/0001104659-23-117735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465923117735/tm2330650d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117735
- JSON: https://secwatch.observer/filing/0001104659-23-117735.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117735.txt

## Key facts
- Earnings Releases
  NRX Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the third fiscal quarter ending September 30, 2023 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923117735/0001104659-23-117735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.